Ignite Creation Date:
2024-05-06 @ 3:10 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04549584
Status:
TERMINATED
Last Update Posted:
2020-12-17
First Post:
2020-07-30
Brief Title:
Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
Status:
TERMINATED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
due to poor enrolled patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NEO-SMART
Brief Summary:
prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer
Detailed Description:
VimentinPan CK staining will be performed on tissues of patient who visited Seoul National University Hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement
Histologically determined to be a metaplastic breast cancer or tested positive for vimentinPan CK patients decides as the metaplastic breast cancer They evaluate the response rate of the neoadjuvant chemotherapy
Patients with vimentinPan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy
The group of metaplastic breast cancer will enroll 50 people and the group of non-metaplastic breast cancer will enroll 100 people
Histologically determined to be a metaplastic breast cancer or tested positive for vimentinPan CK patients decides as the metaplastic breast cancer They evaluate the response rate of the neoadjuvant chemotherapy
Patients with vimentinPan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy
The group of metaplastic breast cancer will enroll 50 people and the group of non-metaplastic breast cancer will enroll 100 people
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None